Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540017 | 1.00 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL5428085 | 0.93 | MEN1 (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL5539506 | 0.93 | MEN1 (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL8362606 | 0.91 | MEN1 (0.54) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL6759184 | 0.91 | MEN1 (0.54) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL5544295 | 0.91 | MEN1 (0.54) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL5482902 | 0.91 | MEN1 (0.54) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL7254369 | 0.91 | TSHR (0.46) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL7248312 | 0.91 | TSHR (0.46) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL7249899 | 0.88 | MEN1 (0.45) | TSHRCYP3A4MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387954-A1 | LONG-LIVED REDOX-ACTIVE MOLECULES WITH LOW REDOX POTENTIAL | President and Fellows of Harvard College (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240136561-A1 | ELECTRICAL REGENERATION OF ELECTROLYTES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-04-25 | — | — | US | disclosed |
| EP-4351662-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794585-A | Radioimmunoconjugates and checkpoint inhibitor combination therapies | 融合制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117603148-A | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2024-02-27 | — | — | CN | disclosed |
| CN-117482261-A | Combination therapy of radioimmunoconjugates and checkpoint inhibitors | 融合制药公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4292156-A1 | ELECTRICAL REGENERATION OF ELECTROLYTES | President and Fellows of Harvard College (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4289950-A2 | MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF | Revolution Medicines, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-4760049-A | Dye transfer | BASF AKTIENGESELLSCHAFT (DE) | 1988-07-26 | — | — | US | disclosed |
| EP-0251114-A2 | Thienothiophene dyes | BASF Aktiengesellschaft (DE) | 1988-01-07 | — | — | EP | disclosed |
| US-4672109-A | Method for selective methylation of erythromycin A derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1987-06-09 | — | — | US | disclosed |
| EP-0158467-A2 | Method for selective methylation of erythromycin a derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1985-10-16 | — | — | EP | disclosed |
| US-4487781-A | HEAT RESISTANCE; PHOTOSTABILITY | SANKYO COMPANY LIMITED (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4415494-A | BLUE-TO-BLACK COLORFAST DISPERSE, NITRO DYES; DIAZOTIZING A P-NITROANILINE AND COUPLING WITH AN N-SUBSTITUTED 1-NAPHTHYLAMINE | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| EP-0036545-A1 | Water insoluble monoazo dyes, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1981-09-30 | — | — | EP | disclosed |
| US-4259350-A | PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK | SANKYO COMPANY LIMITED (JP) | 1981-03-31 | — | — | US | disclosed |
| US-4175185-A | ESTERIFICATION, IMINOHALOGENATION, ETHERIFICATION, HYDROLYSIS, DEESTERIFICATION | MEIJI SEIKA KAISHA LTD. (JP) | 1979-11-20 | — | — | US | disclosed |
| US-4009193-A | OPTICAL BRIGHTENERS FOR ACRYLONITRILE POLYMERS | BASF AKTIENGESELLSCHAFT (DT) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | CEP170, PIN1, FKBP3 | TSHR 4480/4885CYP3A4 2870/4885MEN1 2531/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | TSHR 2428/4885CYP3A4 4837/4885MEN1 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.